SpyGlass Pharma reports four‑year trial shows 37% eye‑pressure drop and no safety issues
SpyGlass Pharma announced results from a first‑in‑human, four‑year interim analysis of its Bimatoprost Drug Pad‑IOL (BIM‑IOL) system in patients with mild‑to‑moderate open‑angle glaucoma or ocular hypertension. The study enrolled 23 patients, with 21 evaluable at 48 months, and demonstrated a 37% reduction in mean intra‑ocular pressure while 86% of patients remained off topical drops and no product‑related adverse events were reported. The company said it will pursue a 505(b)(2) New Drug Application with the FDA.
Why it matters
The data support the safety and efficacy of SpyGlass’s sustained‑release glaucoma implant, moving the program closer to an FDA submission and potential commercialization, which could drive future revenue. The company’s press release notes the results will be used to advance the program toward a New Drug Application.
Key facts
- 1The trial enrolled 23 patients across three dosage groups (75 µg, 150 µg and 300 µg). investing.com
- 2At the four‑year timepoint, 21 patients remained evaluable after two were lost (one relocated, one discontinued due to cancer). investing.com
- 3Mean intra‑ocular pressure fell 37% from 25.1 ± 2.5 mmHg at baseline to 15.9 ± 2.8 mmHg. investing.com
- 486% of patients (18 of 21) remained off all topical IOP‑lowering drops. investing.com
- 590% of patients maintained best‑corrected distance visual acuity of ≥20/25. investing.com
- 6No product‑related adverse events were reported during the four‑year follow‑up. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.